COVID-19 outcomes in persons with multiple sclerosis treated with rituximab

BACKGROUND: Outcomes of COVID-19 in PwMS (persons with Multiple Sclerosis) on immunosuppressive therapies, particularly B-cell depletors, can be unpredictable. There has been a concern for postponing or avoiding use of Rituximab (RTX) during the COVID-19 pandemic. We report the course and outcomes o...

Descripción completa

Detalles Bibliográficos
Autores principales: Iyer, Rajesh B, S, Raghavendra, M, Javeria Nooraine, R, Jaychandran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8579699/
https://www.ncbi.nlm.nih.gov/pubmed/35158435
http://dx.doi.org/10.1016/j.msard.2021.103371

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8579699/
https://www.ncbi.nlm.nih.gov/pubmed/35158435
http://dx.doi.org/10.1016/j.msard.2021.103371

Ejemplares similares